RE:CAR-T updateMarch 12, 2024 - Mustang Bio and City of Hope’s chimeric antigen receptor T-cell (CAR-T) therapy for recurrent glioblastoma has resulted in stable disease or better in half of the subjects in a phase 1 clinical trial, including one patient whose cancer has not recurred for more than five years.
The trial, described March 7 in Nature Medicine, is the largest reported so far on a CAR-T therapy in glioblastoma.
Given that systemic administration of CAR-T therapy is linked to dangerous side effects in the brain—specifically, a set of symptoms called immune effector cell-associated neurotoxicity syndrome, or ICANS—the researchers initially worried that injecting CAR-Ts directly into the brain would go very wrong.
Surprisingly, there was no neurotoxicity in any of the patients. Some developed headaches and fevers for a few days, but that was the extent of their side effects.
https://www.fiercebiotech.com/research/mustang-bio-and-city-hope-car-t-therapy-glioblastoma-extends-survival-phase-1-trial